Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 18/20 | 0.72 |
| ▸ | ROCK1 | Q13464 | 12/20 | 0.69 |
| ▸ | CLK2 | P49760 | 1/20 | 0.64 |
| ▸ | BLK | P51451 | 1/20 | 0.64 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.64 |
| ▸ | STK3 | Q13188 | 1/20 | 0.64 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.64 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.64 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.64 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.64 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.50 |
| ▸ | SLC2A3 | P11169 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15639834 | 0.95 | ROCK2 (0.75) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| SCHEMBL17040576 | 0.84 | ROCK2 (1.00) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| Belumosudil SCHEMBL878258 | 0.83 | ROCK2 (0.91) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| SCHEMBL17038102 | 0.82 | ROCK2 (1.00) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| SCHEMBL15638917 | 0.82 | ROCK2 (0.85) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| SCHEMBL32670252 | 0.81 | ROCK2 (0.75) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| SCHEMBL17025848 | 0.81 | ROCK2 (0.75) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| SCHEMBL24862626 | 0.80 | ROCK2 (0.52) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| Belumosudil SCHEMBL878202 | 0.79 | ROCK2 (1.00) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| Belumosudil SCHEMBL29364140 | 0.79 | ROCK2 (1.00) | ROCK2ROCK1CLK2BLKCSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034127-A1 | TREATMENT OF GVHD | KADMON CORP LLC (FR) | 2026-02-05 | — | — | US | disclosed |
| EP-4116293-A2 | RHO KINASE INHIBITORS | Kadmon Corporation, LLC (US) | 2023-01-11 | — | — | EP | disclosed |
| US-20220395501-A1 | TREATMENT OF GVHD | KADMON CORP LLC (US) | 2022-12-15 | — | — | US | disclosed |
| US-11311541-B2 | Treatment of GVHD | KADMON CORPORATION, LLC (US) | 2022-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034127-A1 | TREATMENT OF GVHD | ROCK2, RHOA, MYH2 | ROCK2 1/4885ROCK1 4/4885CLK2 337/4885 |
| US-20220395501-A1 | TREATMENT OF GVHD | ROCK2, ROCK1, RHOXF2 | ROCK2 1/4885ROCK1 2/4885CLK2 1806/4885 |
| US-11311541-B2 | Treatment of GVHD | ROCK2, ROCK1, RHOA | ROCK2 1/4885ROCK1 2/4885CLK2 2335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.